BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of “Moderate Buy” from Brokerages

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $140.0314.

BNTX has been the subject of a number of research reports. JPMorgan Chase & Co. cut their target price on shares of BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a research report on Thursday, October 23rd. TD Cowen restated a “hold” rating on shares of BioNTech in a research note on Monday, November 3rd. UBS Group raised shares of BioNTech to a “hold” rating in a report on Thursday, December 4th. Morgan Stanley reissued an “overweight” rating and set a $134.00 target price on shares of BioNTech in a report on Monday, November 3rd. Finally, Bank of America cut their price target on BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd.

BioNTech Stock Down 2.6%

BNTX stock opened at $113.75 on Monday. The stock has a market cap of $25.61 billion, a P/E ratio of -43.25 and a beta of 1.49. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. The stock’s fifty day simple moving average is $101.09 and its two-hundred day simple moving average is $103.79. BioNTech has a 1-year low of $81.20 and a 1-year high of $124.98.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The company had revenue of $1.78 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the prior year, the company earned $0.81 earnings per share. The firm’s revenue was up 22.0% on a year-over-year basis. Analysts expect that BioNTech will post -3.88 EPS for the current year.

Institutional Trading of BioNTech

Several institutional investors and hedge funds have recently modified their holdings of BNTX. Rhenman & Partners Asset Management AB increased its stake in BioNTech by 0.3% during the 2nd quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company’s stock valued at $3,819,000 after purchasing an additional 120 shares in the last quarter. Kennedy Capital Management LLC grew its holdings in shares of BioNTech by 0.8% during the second quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock valued at $1,748,000 after buying an additional 127 shares during the last quarter. Probity Advisors Inc. increased its position in shares of BioNTech by 5.7% during the third quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock worth $247,000 after acquiring an additional 135 shares in the last quarter. Profund Advisors LLC increased its position in shares of BioNTech by 3.6% during the second quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock worth $459,000 after acquiring an additional 149 shares in the last quarter. Finally, Mackenzie Financial Corp raised its holdings in shares of BioNTech by 4.0% in the 3rd quarter. Mackenzie Financial Corp now owns 4,290 shares of the company’s stock worth $418,000 after acquiring an additional 165 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.